Shots: The companies jointly enter into P-I trial evaluating the clinical benefits, combining immune stimulator, Immuntep’s eftilagimod alpha (“efti” or “IMP321”), with Merck and Pfizer’s avelumab. Alliances will jointly develop […]readmore
Tags : Merck KGaA and Pfizer